Additional Information
Book Details
Abstract
The most comprehensive set of quality guidelines available to the pharmacy profession.
More than half a century ago, ASHP® developed its earliest proposed practice standard—the Proposed Minimum Standards for Pharmacies in Hospitals.
Today, ASHP continues to foster concrete improvements in pharmacy practice and in the therapeutic use of drugs with its annual compilation of ASHP guidance documents: ASHP Best Practices. These guidance documents have stimulated improvements in pharmacy practice and operations, influenced accreditation standards, laws, and regulations (both in the United States and in other countries), and contributed to an awareness among consumers and policymakers of the vital patient care role of pharmacists.
INSIDE: ASHP positions and more than 70 ASHP guidance documents of varying scope that provide ongoing advice to practitioners and health systems to help improve the medication-use process, patient care and safety, and patient outcomes and quality of life.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Contents | 3 | ||
| Page Locator for Guidance Documents by Type and Title | 14 | ||
| Acknowledgments | 17 | ||
| Introduction | 19 | ||
| Mission Statement of the American Society of Health-System Pharmacists (ASHP) | 22 | ||
| Vision Statement of the American Society of Health-System Pharmacists (ASHP) | 22 | ||
| ASHP Policy Positions, Statements, Guidelines, and Technical Assistance Bulletins | 23 | ||
| Automation and Information Technology | 25 | ||
| Positions | 26 | ||
| Therapeutic Indication in Clinical Decision Support Systems (1608) | 26 | ||
| Automated Preparation and Dispensing Technology for Sterile Preparations (1617) | 26 | ||
| Online Pharmacy and Internet Prescribing (1529) | 26 | ||
| Risk Assessment of Health Information Technology (1418) | 26 | ||
| Interoperability of Patient-Care Technologies (1302) | 26 | ||
| Pharmacist’s Role in Health Care Information Systems (1211) | 26 | ||
| Clinical Decision Support Systems (1212) | 26 | ||
| Definition of Meaningful Use of Health Information Technology (1006) | 27 | ||
| Role of Pharmacists in Safe Technology Implementation(1020) | 27 | ||
| Electronic Health and Business Technology and Services(0712) | 27 | ||
| Electronic Information Systems (0507) | 27 | ||
| Computerized Prescriber Order Entry (0105) | 27 | ||
| Telepharmacy (9920) | 27 | ||
| Regulation of Automated Drug Distribution Systems (9813) | 28 | ||
| Statements\r | 29 | ||
| ASHP Statement on Bar-Code-Enabled Medication Administration Technology | 29 | ||
| ASHP Statement on Bar-Code Verification During Inventory, Preparation, and Dispensing of Medications | 32 | ||
| ASHP Statement on the Pharmacist’s Role in Clinical Informatics | 35 | ||
| ASHP Statement on the Pharmacist’s Role with Respect to Drug Delivery Systems and Administration Devices | 39 | ||
| ASHP Statement on the Pharmacy Technician’s Role in Pharmacy Informatics | 41 | ||
| ASHP Statement on Use of Social Media by Pharmacy Professionals | 44 | ||
| Guidelines | 47 | ||
| ASHP Guidelines on the Design of Database-Driven Clinical Decision Support: Strategic Directions for Drug Database and Electronic Health Records Vendors | 47 | ||
| ASHP Guidelines on Pharmacy Planning for Implementation of Computerized Provider-Order-Entry Systems in Hospitals and Health Systems | 53 | ||
| ASHP Guidelines on Remote Medication Order Processing | 73 | ||
| ASHP Guidelines on the Safe Use of Automated Compounding Devices for the Preparation of Parenteral Nutrition Admixtures | 79 | ||
| ASHP Guidelines on the Safe Use of Automated Dispensing Devices | 84 | ||
| Drug Distribution and Control | 91 | ||
| Positions\r | 92 | ||
| Redistribution of Unused Medications (0611) | 92 | ||
| Pharmaceutical Counterfeiting (0401) | 92 | ||
| Pharmacy Drug Theft (0303) | 92 | ||
| Pharmacist’s Role in Drug Procurement, Distribution, Surveillance, and Control (0232) | 92 | ||
| Optimizing the Medication-Use Process (9903) | 92 | ||
| Procurement\r | 92 | ||
| Guidelines | 93 | ||
| ASHP Guidelines on Managing Drug Product Shortages in Hospitals and Health Systems | 93 | ||
| ASHP Guidelines for Selecting Pharmaceutical Manufacturers and Suppliers | 100 | ||
| Preparation and Handling | 102 | ||
| Positions\r | 102 | ||
| Pharmaceutical Waste (0903) | 102 | ||
| Safe Disposal of Patients’ Home Medications (0614) | 102 | ||
| Safe and Effective Extemporaneous Compounding (0616) | 102 | ||
| Guidelines | 103 | ||
| ASHP Guidelines on Compounding Sterile Preparations | 103 | ||
| ASHP Guidelines on Handling Hazardous Drugs | 123 | ||
| ASHP Guidelines on Pharmacy-Prepared Ophthalmic Products | 143 | ||
| Technical Assistance Bulletin | 145 | ||
| ASHP Technical Assistance Bulletin on Compounding Nonsterile Products in Pharmacies | 145 | ||
| Distribution | 152 | ||
| Positions\r | 152 | ||
| Technician-Checking-\x0BTechnician Programs (0310) | 152 | ||
| Dispensing by Nonpharmacists and Nonprescribers (0010) | 152 | ||
| Statements | 153 | ||
| ASHP Statement on Pharmacist’s Responsibility for Distribution and Control of Drug Products | 153 | ||
| ASHP Statement on Unit Dose Drug Distribution | 154 | ||
| Technical Assistance Bulletin | 155 | ||
| ASHP Technical Assistance Bulletin on Hospital Drug Distribution and Control | 155 | ||
| ASHP Technical Assistance Bulletin on Repackaging Oral Solids and Liquids in Single Unit and Unit Dose Packages | 164 | ||
| ASHP Technical Assistance Bulletin on Single Unit and Unit Dose Packages of Drugs | 166 | ||
| Education and Training | 169 | ||
| Positions\r | 170 | ||
| Pharmacy Technician Training and Certification (1609) | 170 | ||
| Developing Leadership Competencies (1611) | 170 | ||
| Interprofessional Education and Training (1612) | 170 | ||
| Cultural Competency (1613) | 170 | ||
| Pharmacy Resident and Student Roles in New Practice Models (1316) | 170 | ||
| Education and Training in Health Care Informatics (1317) | 170 | ||
| Preceptor Skills and Abilities (1201) | 170 | ||
| Qualifications of Pharmacy Technicians in Advanced Roles (1203) | 170 | ||
| Quality of Pharmacy Education and Expansion of Colleges of Pharmacy (1108) | 171 | ||
| Residency Equivalency (1109) | 171 | ||
| Pharmacy Internships (1110) | 171 | ||
| State-Specific Requirements for Pharmacist Continuing Education (1111) | 171 | ||
| Innovative Residency Models (1112) | 171 | ||
| Employment Classification and Duty Hours of Pharmacy Residents (1008) | 171 | ||
| Pharmacy Student Experiences in Medically Underserved Areas (0913) | 171 | ||
| Pharmacy Expertise in the Preparation and Handling of Injectable Medications (0915) | 171 | ||
| Continuing Professional Development (0916) | 172 | ||
| Pharmacy Residency Training (0917) | 172 | ||
| Collaboration Regarding Experiential Education (0804) | 172 | ||
| Requirement for Residency (0701) | 172 | ||
| Residency Programs (0704) | 172 | ||
| ASHP Guidelines, Statements, and Professional Policies as an Integral Part of the Educational Process (0705) | 172 | ||
| Communication Among Health-System Pharmacy Practitioners, Patients, and Other Health Care Providers (0510) | 172 | ||
| Practice Sites for Colleges of Pharmacy (0315) | 172 | ||
| Licensure for Pharmacy Graduates of Foreign Schools(0323) | 173 | ||
| Public Funding for Pharmacy Residency Training (0325) | 173 | ||
| Residency Training for Pharmacists Who Provide Direct Patient Care (0005) | 173 | ||
| Career Counseling (8507) | 173 | ||
| Endorsed Documents | 174 | ||
| Definitions of Pharmacy Residencies and Fellowships | 174 | ||
| Ethics | 177 | ||
| Positions | 178 | ||
| Pharmacist Role in Capital Punishment (1531) | 178 | ||
| Pharmacist’s Role on Ethics Committees (1403) | 178 | ||
| Ethical Use of Placebos in Clinical Practice (1116) | 178 | ||
| Pharmacist’s Right of Conscience and Patient’s Right of Access to Therapy (0610) | 178 | ||
| Patient’s Right to Choose (0013) | 178 | ||
| ASHP Position on Assisted Suicide (9915) | 178 | ||
| Nondiscriminatory Pharmaceutical Care (9006) | 178 | ||
| Statements | 179 | ||
| ASHP Statement on Leadership as a Professional Obligation | 179 | ||
| ASHP Statement on Pharmacist’s Decision-making on Assisted Suicide | 181 | ||
| ASHP Statement on Professionalism | 184 | ||
| Guidelines | 187 | ||
| ASHP Guidelines on Pharmacists’ Relationships with Industry | 187 | ||
| Endorsed Document | 188 | ||
| Code of Ethics for Pharmacists | 188 | ||
| Formulary Management (Medication-Use Policy Development) | 189 | ||
| Positions | 190 | ||
| Pharmacogenomics (1104) | 190 | ||
| Medications Derived from Biologic Sources (0809) | 190 | ||
| Generic Substitution of Narrow Therapeutic Index Drugs (0817) | 190 | ||
| Expression of Therapeutic Purpose of Prescribing (0305) | 190 | ||
| Appropriate Dosing of Medications in Patient Populations with Unique Needs (0228) | 190 | ||
| Medication Formulary System Management (0102) | 190 | ||
| Gene Therapy (0103) | 190 | ||
| Role of Pharmacists and Business Leaders in Health Care Services and Policies (9819) | 191 | ||
| Standardization of Drug Medication Formulary Systems (9601) | 191 | ||
| Medical Devices (9106) | 191 | ||
| Therapeutic Interchange (8708) | 191 | ||
| Statements | 192 | ||
| ASHP Statement on the Pharmacy and Therapeutics Committee and the Formulary System | 192 | ||
| ASHP Statement on the Use of Medications for Unlabeled Uses | 195 | ||
| Guidelines | 197 | ||
| ASHP Guidelines on Medication-Use Evaluation | 197 | ||
| ASHP Guidelines on the Pharmacy and Therapeutics Committee and the Formulary System | 200 | ||
| Endorsed Document | 210 | ||
| Principles of a Sound Drug Formulary System | 210 | ||
| Government, Law, and Regulation | 215 | ||
| Positions\r | 216 | ||
| Drug Product Supply Chain Integrity (1602) | 216 | ||
| Timely Board of Pharmacy Licensing (1621) | 216 | ||
| Inclusion of Drug Product Shortages in State Price-gouging Laws (1622) | 216 | ||
| Pharmacist Participation in Health Policy Development (1501) | 216 | ||
| Pharmacist Recognition as a Healthcare Provider (1502) | 216 | ||
| Premarketing Comparative Clinical Studies (1506) | 216 | ||
| Funding, Expertise, and Oversight of State Boards of Pharmacy (1507) | 216 | ||
| Support for FDA Expanded Access (Compassionate Use) Program (1508) | 217 | ||
| Approval of Biosimilar Medications (1509) | 217 | ||
| Development of Abuse-Resistant Narcotics (1512) | 217 | ||
| Quality Patient Medication Information (1513) | 217 | ||
| Automatic Stop Orders (1405) | 217 | ||
| Federal and State Regulation of Compounding (1406) | 217 | ||
| 340B Drug Pricing Program Sustainability (1407) | 218 | ||
| State Prescription Drug Monitoring Programs (1408) | 218 | ||
| Access to Oral Contraceptives Through an Intermediate Category of Drug Products (1410) | 218 | ||
| Expedited Pathways for FDA Drug Approval (1411) | 218 | ||
| FDA Oversight of Laboratory-Developed Tests (1412) | 218 | ||
| Regulation of Telepharmacy Services (1310) | 218 | ||
| Regulation of Centralized Order Fulfillment (1311) | 219 | ||
| DEA Scheduling of Hydrocodone Combination Products (1314) | 219 | ||
| DEA Scheduling of Controlled Substances (1315) | 219 | ||
| Pharmacy Technicians (1216) | 219 | ||
| Stable Funding for HRSA Office of Pharmacy Affairs (1219) | 219 | ||
| Globalization of Clinical Trials (1223) | 219 | ||
| Medical Marijuana (1101) | 220 | ||
| Agricultural Use of Hormone and Prohormone Therapies (1102) | 220 | ||
| Direct-to-Consumer Clinical Genetic Tests (1103) | 220 | ||
| Poison Control Center Funding (1121) | 220 | ||
| Health Insurance Coverage for U.S. Residents (1001) | 220 | ||
| Risk Evaluation and Mitigation Strategies (1002) | 221 | ||
| FDA Authority on Recalls (1003) | 221 | ||
| Postmarketing Comparative Clinical and Pharmacoeconomic Studies (1004) | 221 | ||
| Regulation of Home Medical Equipment Medication Products and Devices (1007) | 221 | ||
| Preservation of Antimicrobials for Medical Treatment (1009) | 221 | ||
| Use of Surrogate Endpoints for FDA Approval of Drug Uses (1011) | 221 | ||
| Regulation of Interstate Pharmacy Practice (0909) | 222 | ||
| Regulation of Dietary Supplements (0811) | 222 | ||
| Medicare Prescription Drug Benefit (0813) | 222 | ||
| Federal Review of Anticompetitive Practices by Drug Product Manufacturers (0814) | 222 | ||
| FDA Authority to Prohibit Reuse of Brand Names (0719) | 222 | ||
| Minimum Effective Doses (0602) | 222 | ||
| Postmarketing Safety Studies (0515) | 222 | ||
| Mandatory Registry of Clinical Trials (0516) | 223 | ||
| Importation of Pharmaceuticals (0413) | 223 | ||
| Intermediate Category of Drugs (0220) | 223 | ||
| Greater Access to Less Expensive Generic Drugs (0222) | 223 | ||
| FDA’s Public Health Mission (0012) | 223 | ||
| Generic Pharmaceutical Testing (9010) | 224 | ||
| Statements | 225 | ||
| ASHP Statement on Criteria for an Intermediate Category of Drug Products | 225 | ||
| ASHP Statement on the Over-the-Counter Availability of Statins | 228 | ||
| ASHP Statement on Principles for Including Medications and Pharmaceutical Care in Health Care Systems | 231 | ||
| Medication Misadventures | 233 | ||
| Positions\r | 234 | ||
| Statutory Protection for Medication-Error Reporting (1505) | 234 | ||
| Support for Second Victims (1524) | 234 | ||
| Standardization of Small-Bore Connectors to Avoid Wrong-Route Errors (1530) | 234 | ||
| Just Culture (1115) | 234 | ||
| Just Culture and Reporting Medication Errors (1021) | 234 | ||
| Minimizing the Use of Abbreviations (0604) | 234 | ||
| Drug Names, Labeling, and Packaging Associated with Medication Errors (0020) | 234 | ||
| Medication Errors and Risk Management (0021) | 235 | ||
| Medication Misadventures (9805) | 235 | ||
| Human Factors Concepts (9609) | 235 | ||
| Statements | 236 | ||
| ASHP Statement on Reporting Medical Errors | 236 | ||
| ASHP Statement on the Role of the Medication Safety Leader | 237 | ||
| Guidelines | 241 | ||
| ASHP Guidelines on Adverse Drug Reaction Monitoring and Reporting | 241 | ||
| ASHP Guidelines on Preventing Medication Errors in Hospitals | 244 | ||
| ASHP Guidelines on Preventing Medication Errors with Chemotherapy and Biotherapy | 253 | ||
| Medication Therapy and Patient Care | 279 | ||
| Organization and Delivery of Services | 280 | ||
| Positions\r | 280 | ||
| Patient Experience (1616) | 280 | ||
| Integrated Approach for the Pharmacy Enterprise (1618) | 280 | ||
| Preventing Exposure to Allergens (1619) | 280 | ||
| Patient Adherence Programs as Part of Health Insurance Coverage (1504) | 280 | ||
| Complementary and Alternative Medicine in Patient Care (1511) | 280 | ||
| Impact of Insurance Coverage Design on Patient Care Decision (1520) | 280 | ||
| Pharmacist’s Role in Population Health Management (1523) | 280 | ||
| Standardization of Doses (1525) | 281 | ||
| Standardization of Oral Liquid Medication Concentrations (1401) | 281 | ||
| Documentation of Patient-Care Services in the Permanent Health Record (1419) | 281 | ||
| Standardization of Intravenous Drug Concentrations (1306) | 281 | ||
| Medication Overuse (1312) | 281 | ||
| Drug-Containing Devices (1313) | 281 | ||
| Qualifications and Competencies Required to Prescribe Medications (1202) | 281 | ||
| Transitions of Care (1208) | 281 | ||
| Pharmacist Prescribing in Interprofessional Patient Care (1213) | 282 | ||
| Pharmacist’s Role in Team-Based Care (1215) | 282 | ||
| Collaborative Drug Therapy Management (1217) | 282 | ||
| Medication Adherence (1222) | 282 | ||
| Patient-Reported Outcomes Tools (1107) | 282 | ||
| Pharmacist Accountability for Patient Outcomes (1114) | 282 | ||
| Pharmacists’ Role in Medication Reconciliation (1117) | 283 | ||
| Medication Therapy Management (1005) | 283 | ||
| Patient Access to Pharmacy Services in Small and Rural Hospitals (1022) | 283 | ||
| Scope and Hours of Pharmacy Services (1023) | 283 | ||
| Health-System Use of Medications and Administration Devices Supplied Directly to Patients (0806) | 283 | ||
| Pharmacist’s Leadership Role in Anticoagulation Therapy Management (0816) | 283 | ||
| Standard Drug Administration Schedules (0707) | 283 | ||
| Universal Influenza Vaccination (0601) | 284 | ||
| Health Care Quality Standards and Pharmacy Services (0502) | 284 | ||
| Health-System Facility Design (0505) | 284 | ||
| Mandatory Tablet Splitting for Cost Containment (0525) | 284 | ||
| Performance Improvement (0202) | 284 | ||
| Pharmacy Benefits for the Uninsured (0101) | 284 | ||
| Pharmacist Validation of Information Related to Medications (9921) | 284 | ||
| Collaborative Drug Therapy Management Activities (9801) | 284 | ||
| Medication Administration by Pharmacists (9820) | 285 | ||
| Statements | 286 | ||
| ASHP Statement on Confidentiality of Patient Health Care Information | 286 | ||
| ASHP Statement on the Health-System Pharmacist’s Role in National Health Care Quality Initiatives | 287 | ||
| ASHP–SHM Joint Statement on Hospitalist–Pharmacist Collaboration | 289 | ||
| ASHP Statement on Pharmaceutical Care | 293 | ||
| ASHP Statement on the Roles of Pharmacy Technicians | 296 | ||
| Guidelines | 299 | ||
| ASHP Guidelines on Documenting Pharmaceutical Care in Patient Medical Records | 299 | ||
| ASHP Guidelines on Pharmacist-Conducted Patient Education and Counseling | 302 | ||
| ASHP Guidelines on the Pharmacist’s Role in the Development, Implementation, and Assessment of Critical Pathways | 305 | ||
| ASHP Guidelines on a Standardized Method for Pharmaceutical Care | 311 | ||
| Specific Practice Areas | 314 | ||
| Positions\r | 314 | ||
| Safety of Intranasal Route as an Alternative Route of Administration (1601) | 314 | ||
| Stewardship of Drugs with Potential for Abuse (1603) | 314 | ||
| Appropriate Use of Antipsychotic Drug Therapies (1604) | 314 | ||
| Safety of Epidural Steroid Injections (1605) | 314 | ||
| Drug Dosing in Renal Replacement Therapy (1606) | 314 | ||
| Use of Methadone to Treat Pain (1607) | 314 | ||
| Controlled Substance Diversion and Patient Access (1614) | 314 | ||
| Naloxone Availability (1510) | 314 | ||
| Safety and Effectiveness of Ethanol Treatment for Alcohol Withdrawal Syndrome (1514) | 315 | ||
| Chemotherapy Parity (1516) | 315 | ||
| Documentation of Penicillin Allergy as a Component of Antimicrobial Stewardship (1517) | 315 | ||
| Prescription Drug Abuse (1526) | 315 | ||
| Pharmacist’s Role in Urgent and Emergency Situations (1527) | 315 | ||
| Appropriate Use of Testosterone (1536) | 315 | ||
| Safe Use of Radiopharmaceuticals (1402) | 315 | ||
| Safe Use of Fentanyl Transdermal System Patches (1404) | 315 | ||
| Education About Performance-Enhancing Substances (1305) | 315 | ||
| Pharmacists’ Role in Immunization (1309) | 316 | ||
| Pharmacist’s Role in Accountable Care Organizations (1214) | 316 | ||
| Criteria for Medication Use in Geriatric Patients (1221) | 316 | ||
| Tobacco and Tobacco Products (1224) | 316 | ||
| Safe and Effective Use of IV Promethazine (1105) | 316 | ||
| Pain Management (1106) | 317 | ||
| Pharmacist’s Role in Providing Care for an Aging Population (0902) | 317 | ||
| Pharmacist Role in the Health Care (Medical) Home (0908) | 317 | ||
| Safe and Effective Use of Heparin in Neonatal Patients (0912) | 317 | ||
| Pharmacist Support for Dying Patients (0307) | 317 | ||
| Interventions to Reduce High-Risk Behavior in Intravenous Drug Users (9711) | 317 | ||
| Primary and Preventive Care (9407) | 317 | ||
| Statements | 318 | ||
| ASHP Statement on the Pharmacist’s Role in Antimicrobial Stewardship and Infection Prevention and Control | 318 | ||
| ASHP Statement on the Pharmacist’s Role in Clinical Pharmacogenomics | 321 | ||
| ASHP Statement on the Pharmacist’s Role in Clinical Pharmacokinetic Monitoring | 324 | ||
| ASHP Statement on the Pharmacist’s Role in Medication Reconciliation | 326 | ||
| ASHP Statement on the Pharmacist’s Role in Primary Care | 329 | ||
| ASHP Statement on the Pharmacist’s Role in Substance Abuse Prevention, Education, and Assistance | 332 | ||
| ASHP Statement on Pharmacy Services to the Emergency Department | 336 | ||
| ASHP Statement on Racial and Ethnic Disparities in Health Care | 339 | ||
| ASHP Statement on the Role of Health-System Pharmacists in Emergency Preparedness | 344 | ||
| ASHP Statement on the Role of Health-System Pharmacists in Public Health | 346 | ||
| ASHP Statement on the Use of Dietary Supplements | 351 | ||
| Guidelines | 356 | ||
| ASHP Guidelines on Emergency Medicine Pharmacist Services | 356 | ||
| ASHP Guidelines on Pharmacist Involvement in HIV Care | 371 | ||
| ASHP Guidelines on the Pharmacist’s Role in Immunization | 395 | ||
| ASHP Guidelines on the Pharmacist’s Role in Palliative and Hospice Care | 401 | ||
| ASHP Guidelines on the Pharmacist’s Role in Providing Drug Information | 416 | ||
| ASHP Guidelines for Providing Pediatric Pharmaceutical Services in Organized Health Care Systems | 421 | ||
| ASHP Guidelines on Surgery and Anesthesiology Pharmaceutical Services | 424 | ||
| Pharmaceutical Industry | 433 | ||
| Drug Products, Labeling, and Packaging | 434 | ||
| Positions\r | 434 | ||
| Protecting Workers from Exposure to Hazardous Drugs (1615) | 434 | ||
| Excipients in Drug Products (1528) | 434 | ||
| Nonproprietary Naming of Biological Products (1535) | 434 | ||
| Ensuring Effectiveness, Safety, and Access to OrphanDrug Products (1413) | 434 | ||
| Standardized Clinical Drug Nomenclature (0920) | 434 | ||
| Standardizing Prefixes and Suffixes in Drug Product Names (0720) | 434 | ||
| Mandatory Labeling of the Presence of Latex (0501) | 434 | ||
| Ready-to-Use Packaging for All Settings (0402) | 434 | ||
| Unit Dose Packaging Availability (0309) | 435 | ||
| Drug Shortages (0002) | 435 | ||
| Pediatric Dosage Forms (9707) | 435 | ||
| Use of Color to Identify Drug Products (9608) | 435 | ||
| Expiration Dating of Pharmaceutical Products (9309) | 435 | ||
| Tamper-Evident Packaging on Topical Products (9211) | 435 | ||
| Drug Nomenclature (9011) | 435 | ||
| Codes on Solid Dosage Forms of Prescription Drug Products (8709) | 435 | ||
| Elimination of Apothecary System (8613) | 435 | ||
| Size, Color, and Shape of Drug Products (8310) | 435 | ||
| Marketing | 436 | ||
| Positions\r | 436 | ||
| Promotion of Off-Label Uses (1620) | 436 | ||
| Ban on Direct-to-Consumer Advertising for Prescription Drugs and Medication-Containing Devices (1624) | 436 | ||
| Identification of Prescription Drug Coverage and Eligibility for Patient Assistance Programs (1521) | 436 | ||
| Manufacturer-Sponsored Patient Assistance Programs (1420) | 436 | ||
| Pharmaceutical Distribution Systems (1016) | 436 | ||
| Restricted Drug Distribution (0714) | 436 | ||
| Drug Samples (9702) | 437 | ||
| Guideline | 438 | ||
| ASHP Guidelines for Pharmacists on the Activities of Vendors’ Representatives in Organized Health Care Systems | 438 | ||
| Pharmacy Management | 441 | ||
| Positions\r | 442 | ||
| Disposition of Illicit Substances (1522) | 442 | ||
| Pharmacy Department Business Partnerships (1416) | 442 | ||
| Integration of Pharmacy Services in Multifacility Health Systems (1417) | 442 | ||
| Proliferation of Accreditation Organizations (1303) | 442 | ||
| Workload Monitoring and Reporting (0901) | 442 | ||
| Pharmacist Leadership of the Pharmacy Department (0918) | 442 | ||
| Pharmacy Staff Fatigue and Medication Errors (0504) | 443 | ||
| Statements | 444 | ||
| ASHP Statement on the Roles and Responsibilities of the Pharmacy Executive | 444 | ||
| ASHP Statement on Standards-Based Pharmacy Practice in Hospitals and Health Systems | 448 | ||
| Guidelines | 450 | ||
| ASHP Guidelines on Medication Cost Management Strategies for Hospitals and Health Systems | 450 | ||
| ASHP Guidelines on Outsourcing Pharmaceutical Services | 465 | ||
| ASHP Guidelines on Outsourcing Sterile Compounding Services | 472 | ||
| Compensation and Reimbursement | 484 | ||
| Positions\r | 484 | ||
| Payer Processes for Payment Authorization and Coverage Verification (1301) | 484 | ||
| Drug Product Reimbursement (1304) | 484 | ||
| Revenue Cycle Compliance and Management (1205) | 484 | ||
| Value-Based Purchasing (1209) | 484 | ||
| Reimbursement for Unlabeled Uses of FDA-Approved Drug Products (0206) | 484 | ||
| Human Resources | 485 | ||
| Positions\r | 485 | ||
| Career Opportunities for Pharmacy Technicians (1610) | 485 | ||
| Credentialing, Privileging, and Competency Assessment (1415) | 485 | ||
| Financial Management Skills (1207) | 485 | ||
| Board Certification for Pharmacists (1225) | 485 | ||
| Professional Socialization (1113) | 485 | ||
| Credentialing and Privileging by Regulators, Payers, and Providers for Collaborative Drug Therapy Management (0905) | 485 | ||
| Intimidating or Disruptive Behaviors (0919) | 486 | ||
| Education, Prevention, and Enforcement Concerning Workplace Violence (0810) | 486 | ||
| Appropriate Staffing Levels (0812) | 486 | ||
| Image of and Career Opportunities for Hospital and Health-System Pharmacists (0703) | 486 | ||
| Influenza Vaccination Requirements to Advance Patient Safety and Public Health (0615) | 486 | ||
| Staffing for Safe and Effective Patient Care (0201) | 486 | ||
| Pharmacist Recruitment and Retention (0218) | 487 | ||
| Professional Development as a Retention Tool (0112) | 487 | ||
| Drug Testing (9103) | 487 | ||
| Employee Testing (9108) | 487 | ||
| Guidelines | 488 | ||
| ASHP Guidelines on the Recruitment, Selection, and Retention of Pharmacy Personnel | 488 | ||
| Report | 494 | ||
| ASHP Long-Range Vision for the Pharmacy Work Force in Hospitals and Health Systems | 494 | ||
| Practice Settings | 505 | ||
| Positions\r | 506 | ||
| Home Intravenous Therapy (1623) | 506 | ||
| Use of Two Patient Identifiers in the Outpatient Setting (1024) | 506 | ||
| Guidelines | 507 | ||
| ASHP Guidelines on Evaluating and Using Home or Alternate-Site Infusion Service Providers | 507 | ||
| ASHP Guidelines on Home Infusion Pharmacy Services | 512 | ||
| ASHP Guidelines: Minimum Standard for Ambulatory Care Pharmacy Practice | 527 | ||
| ASHP Guidelines: Minimum Standard for Pharmacies in Hospitals | 541 | ||
| ASHP Guidelines on Pharmacy Services in Correctional Facilities | 552 | ||
| Research | 559 | ||
| Positions\r | 560 | ||
| Research on Drug Use in Obese Patients (1515) | 560 | ||
| Institutional Review Boards and Investigational Use of Drugs (0711) | 560 | ||
| Clinical Investigations of Drugs Used in Elderly and Pediatric Patients (0229) | 560 | ||
| Statement | 561 | ||
| ASHP Statement on Pharmaceutical Research in Organized Health-Care Settings | 561 | ||
| Guidelines | 562 | ||
| ASHP Guidelines on Clinical Drug Research | 562 | ||
| ASHP Guidelines for Pharmaceutical Research in Organized Health-Care Settings | 569 | ||
| ASHP Therapeutic Position Statements | 571 | ||
| ASHP Therapeutic Position Statement on the Cessation of Tobacco Use | 572 | ||
| ASHP Therapeutic Position Statement on the Institutional Use of 0.9% Sodium Chloride Injection to Maintain Patency of Peripheral Indwelling Intermittent Infusion Devices | 588 | ||
| ASHP Therapeutic Position Statement on the Role of Pharmacotherapy in Preventing Venous Thromboembolism in Hospitalized Patients | 591 | ||
| ASHP Therapeutic Position Statement on Strategies for Identifying and Preventing Pneumococcal Resistance | 608 | ||
| Therapeutic Monitoring of Vancomycin in Adult Patients: A Consensus Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists | 615 | ||
| ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders | 631 | ||
| ASHP Therapeutic Guidelines | 645 | ||
| Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery | 646 | ||
| Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient | 732 | ||
| Index | 749 |